Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 224

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

Open access
Flaherty, Keith T, Gray, Robert, Chen, Alice, Li, Shuli, Patton, David, Hamilton, Stanley R, Williams, Paul M, Mitchell, Edith P, Iafrate, A John, Sklar, Jeffrey, Harris, Lyndsay N, McShane, Lisa M, Rubinstein, Larry V, Sims, David J, Routbort, Mark, Coffey, Brent, Fu, Tony, Zwiebel, James A, Little, Richard F, Marinucci, Donna, Catalano, Robert, Magnan, Rick, Kibbe, Warren, Weil, Carol, Tricoli, James V, Alexander, Brian, Kumar, Shaji, Schwartz, Gary K, Meric-Bernstam, Funda, Lih, Chih-Jian, McCaskill-Stevens, Worta, Caimi, Paolo, Takebe, Naoko, Datta, Vivekananda, Arteaga, Carlos L, Abrams, Jeffrey S, Comis, Robert, O’Dwyer, Peter J, Conley, Barbara A, for the NCI-MATCH Team · 2020 · JNCI: Journal of the National Cancer Institute

Abstract

Background: The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with refractory malignancies to treatment targeted to potential tumor molecular drivers regardless of cancer histology. Methods: Trial development required assumptions about molecular target prevalence, accrual rates, treatment eligibility, and enrollment rates as well as consideration of logistical requirements. Central tumor profiling was performed with an investigational next-generation DNA–targeted sequencing assay of alterations in 143 genes, and protein expression of protein expression of phosphatase and tensin homolog, mutL homolog 1, mutS homolog 2, and RB transcriptional corepressor 1. Treatments were allocated with a validated computational platform (MATCHBOX). A preplanned interim analysis evaluated assumptions and feasibility in this novel trial. Results: At interim analysis, accrual was robust, tumor biopsies were safe (<1% severe events), and profiling success was 87.3%. Actionable molecular alteration frequency met expectations, but assignment and enrollment lagged due to histology exclusions and mismatch of resources to demand. To address this lag, we revised estimates of mutation frequencies, increased screening sample size, added treatments, and improved assay throughput and efficiency (93.9% completion and 14-day turnaround). Conclusions: The experiences in the design and implementation of the NCI-MATCH trial suggest that profiling from fresh tumor biopsies and assigning treatment can be performed efficiently in a large national network trial. The success of such trials necessitates a broad screening approach and many treatment options easily accessible to patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djz245

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 224

Metadata

Authors
Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., Harris, L. N., McShane, L. M., Rubinstein, L. V., Sims, D. J., Routbort, M., Coffey, B., Fu, T., Zwiebel, J. A., Little, R. F., Marinucci, D., Catalano, R., Magnan, R., Kibbe, W., Weil, C., Tricoli, J. V., Alexander, B., Kumar, S., Schwartz, G. K., Meric-Bernstam, F., Lih, C.-J., McCaskill-Stevens, W., Caimi, P., Takebe, N., Datta, V., Arteaga, C. L., Abrams, J. S., Comis, R., O’Dwyer, P. J., Conley, B. A., & for the NCI-MATCH Team
Venue
JNCI: Journal of the National Cancer Institute
Published
2020-01-10
Volume
112
Issue
10
Pages
1021-1029
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3000144654
Cited by
224
References
9
FWCI
11.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. https://app.cochat.ai/papers/10.1093/jnci/djz245
The paper
Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., Harris, L. N., McShane, L. M., Rubinstein, L. V., Sims, D. J., Routbort, M., Coffey, B., Fu, T., Zwiebel, J. A., Little, R. F., . . . for the NCI-MATCH Team. (2020). The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djz245

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.